SCHEMBL873038

SCHEMBL873038

COC(CCc1ccccc1)OC

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 1/20 0.45
TSHR P16473 1/20 0.43
G6PD P11413 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
CASP1 P29466 1/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 1/20 0.42
TAAR1 Q96RJ0 3/20 0.41
ATM Q13315 1/20 0.41
ANPEP P15144 2/20 0.41
ERAP1 Q9NZ08 2/20 0.41
ERAP2 Q6P179 1/20 0.41
CYP2A6 P11509 1/20 0.41
HTR2A P28223 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29085624 0.88 MMP12 (0.41) MMP12TSHRG6PDALDH1A1POLB
SCHEMBL8071187 0.87 IDO1 (0.45)
SCHEMBL8063607 0.85 L3MBTL1 (0.47)
SCHEMBL28686580 0.84 BCHE (0.61) MMP12
SCHEMBL1977575 0.82 KMT2A (0.45) MMP12TSHRG6PDALDH1A1POLB
SCHEMBL13074081 0.82 MMP12 (0.57) MMP12TSHRG6PDALDH1A1HPGD
SCHEMBL29626913 0.82 MMP12 (0.37) MMP12TSHRG6PDPOLBSMN1; SMN2
SCHEMBL1781296 0.80 LPL (0.47) MMP12SMN1; SMN2
SCHEMBL13626178 0.80 TSHR (0.46) MMP12TSHRG6PDALDH1A1HPGD
SCHEMBL820953 0.80 TSHR (0.46) MMP12TSHRG6PDALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150182656-A1 Perfume Compositions GIVAUDAN S.A. (CH) 2015-07-02 US claimed
US-20150079017-A1 Perfume Compositions GIVAUDAN S.A. (CH) 2015-03-19 US claimed
US-8821847-B2 Perfume compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2014-09-02 US claimed
US-20130230479-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2013-09-05 US claimed
US-20130039876-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2013-02-14 US claimed
US-20130039877-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2013-02-14 US claimed
EP-2049638-B1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES BV (NL) 2012-10-03 EP claimed
EP-2049637-B1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES BV (NL) 2012-05-30 EP claimed
US-20090263344-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2009-10-22 US claimed
US-20090257974-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2009-10-15 US claimed
EP-2049637-A1 PERFUME COMPOSITIONS Givaudan Nederland Services B.V. (NL) 2009-04-22 EP claimed
EP-2049638-A1 PERFUME COMPOSITIONS Givaudan Nederland Services B.V. (NL) 2009-04-22 EP claimed
WO-2008023142-A1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-02-28 WO claimed
WO-2008017820-A1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-02-14 WO claimed
CN-119822945-A Hyacinth fragrance compound, preparation method thereof and hyacinth fragrance type fragrance base 波顿香料股份有限公司 2025-04-15 CN disclosed
CN-117203313-A 2, 4-dimethyloctan-2, 7-dien-4-ol as perfume 西姆莱斯股份公司 2023-12-08 CN disclosed
US-11773092-B1 Pyrido[3,4-b]indol-1-one compounds as antibacterial agents King Faisal University (SA) 2023-10-03 US disclosed
EP-0664780-A1 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 1995-08-02 EP disclosed
US-5426197-A Antiinflammatory, antiallergy or antitumor agents TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 1995-06-20 US disclosed
WO-1995003266-A1 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 1995-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773092-B1 Pyrido[3,4-b]indol-1-one compounds as antibacterial agents IDO1, IDO2, IMPA1 MMP12 1630/4885TSHR 2244/4885G6PD 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.